$784 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 128 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR S&P 500 ETF TRput | $46,969,000 | – | 2,451 | +100.0% | 5.99% | – | |
| ESLT | New | ELBIT SYS LTDord | $29,169,000 | – | 100,618 | +100.0% | 3.72% | – |
| New | MYLAN N Vcall | $12,078,000 | – | 3,000 | +100.0% | 1.54% | – | |
| INCY | New | INCYTE CORP | $11,033,000 | – | 100,000 | +100.0% | 1.41% | – |
| CELJF | New | CELLCOM ISRAEL LTD | $8,793,000 | – | 357,452 | +100.0% | 1.12% | – |
| PRGO | New | PERRIGO CO PLCcall | $8,603,000 | – | 547 | +100.0% | 1.10% | – |
| New | HORIZON PHARMA PLCcall | $6,937,000 | – | 3,500 | +100.0% | 0.88% | – | |
| XLY | New | SELECT SECTOR SPDR TRsbi cons discr | $6,625,000 | – | 89,216 | +100.0% | 0.84% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $5,474,000 | – | 35,000 | +100.0% | 0.70% | – |
| EGLTQ | New | EGALET CORP | $4,284,000 | – | 325,000 | +100.0% | 0.55% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $4,166,000 | – | 40,000 | +100.0% | 0.53% | – |
| HZNP | New | HORIZON PHARMA PLC | $3,964,000 | – | 200,000 | +100.0% | 0.51% | – |
| New | ARRAY BIOPHARMA INCcall | $3,420,000 | – | 7,500 | +100.0% | 0.44% | – | |
| ABUS | New | ARBUTUS BIOPHARMA CORP | $3,075,000 | – | 505,000 | +100.0% | 0.39% | – |
| RTRX | New | RETROPHIN INC | $3,039,000 | – | 150,000 | +100.0% | 0.39% | – |
| TJX | New | TJX COS INC NEW | $2,964,000 | – | 41,496 | +100.0% | 0.38% | – |
| ONCE | New | SPARK THERAPEUTICS INC | $2,921,000 | – | 70,000 | +100.0% | 0.37% | – |
| MDLZ | New | MONDELEZ INTL INCcl a | $2,490,000 | – | 59,475 | +100.0% | 0.32% | – |
| KERX | New | KERYX BIOPHARMACEUTICALS INC | $2,464,000 | – | 700,000 | +100.0% | 0.31% | – |
| ABEO | New | ABEONA THERAPEUTICS INC | $2,430,000 | – | 600,000 | +100.0% | 0.31% | – |
| PTNR | New | PARTNER COMMUNICATIONS CO LTadr | $2,416,000 | – | 617,951 | +100.0% | 0.31% | – |
| CEMP | New | CEMPRA INC | $2,088,000 | – | 75,000 | +100.0% | 0.27% | – |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $2,040,000 | – | 150,000 | +100.0% | 0.26% | – |
| EPZM | New | EPIZYME INC | $1,929,000 | – | 150,000 | +100.0% | 0.25% | – |
| New | NEURODERM LTD | $1,757,000 | – | 85,000 | +100.0% | 0.22% | – | |
| PANW | New | PALO ALTO NETWORKS INC | $1,720,000 | – | 10,002 | +100.0% | 0.22% | – |
| NBRV | New | NABRIVA THERAPEUTICS AGsponsored adr | $1,663,000 | – | 175,000 | +100.0% | 0.21% | – |
| ZGNX | New | ZOGENIX INC | $1,620,000 | – | 120,000 | +100.0% | 0.21% | – |
| OCRX | New | OCERA THERAPEUTICS INC | $1,580,000 | – | 500,000 | +100.0% | 0.20% | – |
| ZFGN | New | ZAFGEN INC | $1,278,000 | – | 40,000 | +100.0% | 0.16% | – |
| HRTX | New | HERON THERAPEUTICS INC | $1,220,000 | – | 50,000 | +100.0% | 0.16% | – |
| ANAC | New | ANACOR PHARMACEUTICALS INC | $1,177,000 | – | 10,000 | +100.0% | 0.15% | – |
| NVAX | New | NOVAVAX INC | $1,061,000 | – | 150,000 | +100.0% | 0.14% | – |
| AXTA | New | AXALTA COATING SYS LTD | $1,029,000 | – | 40,626 | +100.0% | 0.13% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $5,000 | – | 200 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.